



Published in final edited form as:

Org Lett. 2006 February 2; 8(3): 427–430.

## Synthetic Studies on Amphidinolide B1

Amit K. Mandal<sup>†</sup>, John S. Schneekloth Jr.<sup>‡</sup>, Kouji Kuramochi<sup>†</sup>, and Craig M. Crews<sup>\*,†,‡,§</sup>

<sup>†</sup>Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, Connecticut 06520-8103

<sup>‡</sup>Department of Chemistry, Yale University, New Haven, Connecticut 06520-8103

<sup>§</sup>Department of Pharmacology, Yale University, New Haven, Connecticut 06520-8103

### Abstract

The syntheses of three fragments, 2, 3, and 4, of amphidinolide B1 have been accomplished. The 1,3-isomerization of allylic alcohol 10 was accomplished via rhenium oxo catalysis and has been applied successfully in the synthesis. (–)-MIB-catalyzed asymmetric vinylzinc addition to aldehyde 31 and the regio- and stereoselective epoxidation of unsymmetrical divinyl methanol 32 were key steps.

Amphidinolide B1 (**1**), a polyketide-based 26-membered macrolide, was isolated from a culture of the symbiotic marine dinoflagellate *Amphidinium* sp. (strain Y-5) in 1987 by Kobayashi et al.<sup>1,2</sup> There have been several reports of partial syntheses toward **1**; however, no completed total synthesis has been disclosed yet.<sup>3</sup>

In our laboratory, we undertook a multipronged approach toward the synthesis of amphidinolide B1 (**1**) (Scheme 1). One strategy was communicated earlier,<sup>4</sup> whereas this paper represents an alternative strategy. Our previous strategy involved three major C–C bond-forming reactions and one C–O bond-forming reaction. This new retrosynthetic analysis involves two C–C and one C–O bond-forming coupling reactions: Suzuki–Miyaura coupling,<sup>5</sup> an aldol reaction,<sup>6</sup> and macrolactonization using the three fragments **2**, **3**, and **4**. As C–C bond-forming reactions are traditionally more difficult than C–O bond-forming reactions, we hope that this new strategy will increase the efficiency of the synthesis.

The synthesis of fragment **2** began with Brown's crotylation reaction (Scheme 2).<sup>7</sup> The reaction of *trans*-crotonaldehyde and (*E*)-crotyldiisopinocampheylborane (prepared from *trans*-butene, *n*-BuLi, *t*-BuOK, and (+)-Ipc<sub>2</sub>BOMe) in the presence of BF<sub>3</sub>·OEt<sub>2</sub> in THF·Et<sub>2</sub>O at –78 °C produced the allyl alcohol **6** in 50% yield and 14:1 anti/syn selectivity. Silyl protection of the hydroxyl group and a regioselective hydroboration–oxidation sequence furnished alcohol **7**, which was oxidized to the corresponding aldehyde **8** using Dess–Martin periodinane. The asymmetric methylation of **8** with Me<sub>2</sub>Zn and Ti(O<sup>*i*</sup>Pr)<sub>4</sub> was examined with the chiral ligands BINOL and bissulfonamide.<sup>8</sup> Unfortunately, the conversions were unacceptable in both cases (25% and 29%, respectively). However, diastereoselective methylation to obtain **9** was achieved with Seebach's method<sup>9</sup> [Me<sub>2</sub>Zn and Ti(O<sup>*i*</sup>Pr)<sub>4</sub> in the presence of (–)-TADDOL] in 92% yield and a 5–7:1 diastereomeric ratio (based on <sup>1</sup>H NMR). Protection of the free alcohol as a TIPS ether (the minor isomer can be separated at this stage) and selective cleavage of the allylic TBS ether furnished **10** in 70% yield over two steps. At this point, the stage was set to

craig.crews@yale.edu.

**Supporting Information Available:** Experimental procedures and spectroscopic data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

manipulate allylic alcohol **10** to the requisite  $\alpha,\beta$ -unsaturated ketone **12** and to install the remaining stereogenic centers. The 1,3-isomerization of **10** and subsequent oxidation promised to be an atom-efficient method to access ketone **12**.  $\text{Ph}_3\text{SiOREeO}_3$ <sup>10</sup> is currently the most effective catalyst for 1,3-isomerization.<sup>11</sup> When we treated **10** in the presence of 1 mol % catalyst in ether at  $-60^\circ\text{C}$ , complete isomerization to regioisomeric allylic alcohol **11** was observed in 5 min. Oxidation of the alcohol **11** under Dess–Martin periodinane conditions furnished the  $\alpha,\beta$ -unsaturated ketone **12**. Swapping TIPS protection with TBS, Sharpless asymmetric dihydroxylation<sup>12</sup> followed by acetonide formation completed the synthesis of fragment **2**.

The synthesis of fragment **3** started with known vinyl iodide **13**<sup>13</sup> (Scheme 3). Transmetalation with *t*-BuLi in  $\text{Et}_2\text{O}$  and capture of the resulting vinylolithium species with acetaldehyde yielded ( $\pm$ )-allylic alcohol **14**. Sharpless kinetic resolution<sup>14</sup> of ( $\pm$ )-**14** gave the desired epoxide **15** in 85–90% enantiomeric excess (ee) and unreacted alcohol in 25–30% ee as a mixture that proved difficult to separate. The crude mixture was subjected to a Parikh–Doering oxidation to yield easily separable epoxy ketone **16** and the corresponding  $\alpha,\beta$ -unsaturated ketone (not shown). The  $\alpha,\beta$ -unsaturated ketone was subjected to a Luche reduction to produce ( $\pm$ )-allylic alcohol **14**, which was recycled under Sharpless kinetic resolution conditions. The Horner–Wadsworth–Emmons condensation of epoxy ketone **16** with phosphonate in the presence of NaHMDS produced enyne **17** [82% yield, *E/Z* 6:1]. Simultaneous cleavage of TBS ether and the TMS group by TBAF followed by regioselective opening of the epoxide in the presence of  $\text{LiAlH}_4$  in  $\text{Et}_2\text{O}$  furnished diol **18**, which was separated from the minor (*Z*) isomer using column chromatography. Functionalization of the enyne **18** to the 1,3-diene iodide was quite problematic. After exploring several possibilities, we found that the triple bond could be silylstannylated regio- and stereoselectively employing *n*- $\text{Bu}_3\text{SnSiMe}_2\text{Ph}/\text{Pd}(\text{PPh}_3)_4$  to produce functionalized diene **19**.<sup>15</sup> TBAF-mediated removal of the  $\text{PhMe}_2\text{Si}$  group produced stannane **20**. Reaction with  $\text{I}_2$  and selective TBS protection completed the synthesis of fragment **3**.

The synthesis of fragment **4** began with aldehyde **21** (Scheme 4). A nonchelation-controlled  $\text{S}_{\text{E}}2'$  reaction between aldehyde **21** and methallylsilane in the presence of  $\text{BF}_3\cdot\text{OEt}_2$  furnished homoallylic alcohol **22** in 90% yield and  $\geq 95:5$  diastereomeric ratio (dr).<sup>16</sup> Hydroxyl group protection as a TBS ether **23**, followed by oxidative deprotection of the PMB ether, revealed the primary alcohol. The alcohol was then converted to the aldehyde, which was subjected to vinyl-magnesium bromide addition to provide allyl alcohol **24** as a 1.5:1 diastereomeric mixture (based on  $^1\text{H}$  NMR). The allylic alcohol **24** underwent Johnson ortho ester Claisen rearrangement to provide the homologated ethyl ester exclusively as the (*E*) isomer. Reduction to the aldehyde using *i*- $\text{Bu}_2\text{AlH}$  in THF and the Wittig reaction furnished fragment **4** with exclusive (*E*) selectivity.

With all three fragments securely in hand, we sought to explore the possibility of setting up the C11 stereogenic centers by hydroboration and a subsequent (*B*)-alkyl Suzuki–Miyaura coupling reaction<sup>5</sup> to assemble the 1,3-diene. We hoped to induce 1,3-stereocontrol on the basis of Evans' alkyl-directed hydroboration model.<sup>17</sup> We have been able to form the C12–C13 bond successfully using the (*B*)-alkyl Suzuki–Miyaura coupling reaction between (*B*)-alkylborane (derived from regioselective hydroboration of fragment **4**) and ( $\pm$ )-1,3-vinyl iodide fragment **3** (synthesis not shown) to put together the C1–C18 portion of the molecule. However, investigations revealed that 1,3-stereocontrol cannot be achieved with this substrate, as hydroboration of fragment **4** with 9-BBN provided a 1:1 inseparable mixture of diastereoisomers at C11 (amphidinolide B1 numbering).

Considering A values, an alkyl group (i.e.,  $\text{Me} = 1.74$  kcal/mol) imparts more nonbonding interaction than an  $\text{OSiR}_3$  group (i.e.,  $\text{OSiMe}_3 = 0.74$  kcal/mol), presumably because the

SiR<sub>3</sub> group can be turned away to avoid the steric interaction.<sup>18</sup> This explains the loss of  $\pi$ -facial selectivity in our substrate. As separation of the diastereoisomers was not easy, we revised our strategy and decided to use compound **25** as a new fragment for the C1–C12 segment in which the C11 methyl stereogenic center is preinstalled (Scheme 5). Instead of coupling the 1,3-diene iodide fragment **3** to (*B*)-alkylborane (derived by hydroboration from fragment **4**), we decided to couple it to the ate complex **26** derived from the corresponding iodide easily accessible from compound **25** in two steps.<sup>19</sup> Preliminary studies involving ( $\pm$ )-alkenyl iodide fragment **3** and a model alkyl boronate to assemble the 1,3-diene corroborate the feasibility of this strategy.<sup>20</sup>

The synthesis of compound **25** commenced with isoprene monoxide (Scheme 6). TiCl<sub>4</sub>-mediated regioselective and stereoselective opening of the epoxide provided the alcohol, which was protected as a TIPS ether **28**. It was then coupled with propargylmagnesium bromide in the presence of Pd-(PPh<sub>3</sub>)<sub>4</sub> to give acetylene **29** in 83% yield. In parallel, aldehyde **31** was synthesized in two steps via the Wittig reaction, followed by reduction with *i*-Bu<sub>2</sub>AlH. The key strategy is to employ asymmetric addition of alkenylzinc to aldehyde **31** in the presence of Nugent's<sup>21</sup> isoborneol-based (–)-MIB ligand.<sup>22</sup> Hydroboration of the terminal acetylene **29** with freshly prepared dicyclohexylborane proceeds regio-selectively to afford the alkenylborane. Transmetalation of this alkenylborane with Me<sub>2</sub>Zn generates the reactive alkenylzinc reagent in situ. Attempts to carry out the transmetalation at 0 °C, as described in the literature,<sup>23</sup> led to decomposition of the substrate. After extensive experimentation, we found that the reaction could be performed successfully by adding Me<sub>2</sub>Zn followed by (–)-MIB at –78 °C to alkenylborane. The mixture was then warmed to –20 °C over 10 min. The aldehyde **31** in hexane was added via syringe pump over 20 min while warming the mixture to 0 °C to furnish divinyl methanol **32** in 43% yield and  $\geq 95\%$  diastereomeric excess (de). This assembled the full carbon backbone of compound **25**. The next challenge was to functionalize stereoselectively the C7–C8 double bond of this unsymmetrical divinyl methanol **32**.

It is documented that the simple ( $\pm$ )-unsymmetrical divinyl methanols can be subjected to the Sharpless kinetic resolution conditions to synthesize the optically active monoepoxide.<sup>24</sup> However, to the best of our knowledge, Sharpless asymmetric epoxidation has not been applied to desymmetrize a complex unsymmetrical divinyl methanol such as ours in the context of natural product synthesis. We were pleased to find that Sharpless' asymmetric epoxidation provided the C7–C8 monoepoxide in 71% yield (6:1 dr). TIPS protection went uneventfully to furnish **25** in 90% yield.

In conclusion, we have accomplished the synthesis of three fragments, **2**, **3** and **4**. Compound **25** will be used as the new fragment for the C1–C12 segment. 1,3-Isomerization of allylic alcohol via rhenium oxo catalysis has been applied successfully in our synthesis. (–)-MIB-catalyzed asymmetric vinylzinc addition to aldehyde **31**, highly selective late-stage epoxidation of divinyl methanol **32**, and regio- and stereo-selective silylstannylation to synthesize stannane **20** have been used as key steps. Continued advancement of these intermediates toward the eventual total synthesis of **1** are currently ongoing in our laboratory.


#### Acknowledgment

We gratefully acknowledge financial support from NIH (GM062120). J.S.S. acknowledges the American Chemical Society, Division of Medicinal Chemistry, and Aventis Pharmaceuticals for a pre-doctoral fellowship.


#### References

1. Ishibashi M, Ohizumi Y, Hamashima M, Nakamura H, Hirata Y, Sasaki T, Kobayashi J. *J. Chem. Soc., Chem. Commun* 1987:1127.. For reviews: (a) Kobayashi J, Ishibashi M. *Chem. Rev* 1993;93:1753. (b) Chakraborty T, Das S. *Curr. Med. Chem.: Anti-Cancer Agents* 2001;1:131. (c) Kobayashi J,


- Shimbo K, Kubota T, Tsuda M. *Pure Appl. Chem* 2003;75:337. (d) Kobayashi J, Tsuda M. *Nat. Prod. Rep* 2004;21:77. [PubMed: 15039836]
2. Kobayashi J, Ishibashi M, Nakamura H, Ohizumi Y, Yamasu T, Hirata Y, Sasaki T, Ohta T, Nozoe S. *J. Nat. Prod* 1989;52:1036. [PubMed: 2607346]
  3. (a) Kobayashi J, Tsuda M. *Nat. Prod. Rep* 2004;21:77. [PubMed: 15039836] (b) Cid MB, Pattenden G. *Synlett* 1998:540. (c) Cid MB, Pattenden G. *Tetrahedron Lett* 2000;41:7373. (d) Ishiyama H, Takemura T, Tsuda M, Kobayashi J. *Tetrahedron* 1999;55:4583. (e) Ishiyama H, Takemura T, Tsuda M, Kobayashi J. *J. Chem. Soc., Perkin Trans* 1999;1:1163. (f) Ohi K, Shima K, Hamada K, Saito Y, Yamada N, Ohba S, Nishiyama S. *Bull. Chem. Soc. Jpn* 1998;71:2433. (g) Ohi K, Nishiyama S. *Synlett* 1999:573. (h) Ohi K, Nishiyama S. *Synlett* 1999:571. (i) Chakraborty TK, Thippeswamy D, Suresh VR, Jayaprakash S. *Chem. Lett* 1997:563. (j) Chakraborty TK, Thippeswamy D. *Synlett* 1999:150. (k) Chakraborty TK, Thippeswamy D, Jayaprakash S. *J. Ind. Chem. Soc* 1998;75:741. (l) Chakraborty TK, Suresh VR, Vayalakkada R. *Chem. Lett* 1997:565. (m) Eng HM, Myles DC. *Tetrahedron Lett* 1999;40:2275. (n) Eng HM, Myles DC. *Tetrahedron Lett* 1999;40:2279. (o) Lee D-H, Lee S-W. *Tetrahedron Lett* 1997;38:7909. (p) Lee D-H, Rho M-D. *Bull. Korean Chem. Soc* 1998;19:386. (q) Lee D-H, Rho M-D. *Tetrahedron Lett* 2000;41:2573. (r) Zhang W, Carter RG, Yokochi AFT. *J. Org. Chem* 2004;69:2569. [PubMed: 15049660]
  4. Mandal AK, Schneekloth JS Jr, Crews CM. *Org. Lett* 2005;7:3645. [PubMed: 16092840]
  5. Miyaura N, Ishiyama T, Sasaki H, Ishikawa M, Satoh M, Suzuki A. *J. Am. Chem. Soc* 1989;111:314.
  6. Evans DA, Carter PH, Carreira EM, Charette AB, Prunet JA, Lautens M. *J. Am. Chem. Soc* 1999;121:7540.
  7. Brown HC, Bhat KS. *J. Am. Chem. Soc* 1986;108:293.
  8. (a) Takahashi H, Kawakita T, Ohno M, Yoshioka M, Kobayashi S. *Tetrahedron* 1992;48:5691. (b) Kitamoto D, Imma H, Nakai T. *Tetrahedron Lett* 1995;36:1861.
  9. (a) Schmidt B, Seebach D. *Angew. Chem., Int. Ed. Engl* 1991;30:99. (b) von dem Bussche-Hunnefeld JL, Seebach D. *Tetrahedron* 1992;48:5719.
  10. Schoop T, Roesky HW, Noltemeyer M, Schmidt H-G. *Organometallics* 1993;12:571.
  11. Bellemin-Lapponnaz S, Gisie H, Le Ny J-P, Osborn JA. *Angew Chem., Int. Ed. Engl* 1997;36:976.
  12. Walsh PJ, Sharpless KB. *Synlett* 1993:605.
  13. Ashimori A, Bachand B, Calter MA, Govek SP, Overman LE, Poon DJ. *J. Am. Chem. Soc* 1998;120:6488.
  14. Gao Y, Hanson RM, Klunder JM, Ko SY, Masamune H, Sharpless KB. *J. Am. Chem. Soc* 1987;109:5765.
  15. (a) Mitchell TN, Wickenkamp R, Amamria A, Dieke R, Scheider U. *J. Org. Chem* 1987;52:4868. (b) Chenard BL, Van Zyl CM. *J. Org. Chem* 1986;51:3561.
  16. Reetz MT, Kessler K. *J. Org. Chem* 1985;50:5434.
  17. Evans DA, Bartroli J, Godel T. *Tetrahedron Lett* 1982;23:4577.
  18. Eliel, EL.; Wilen, SH.; Mander, LN. *Stereochemistry of Organic Compounds*. New York: John Wiley & Sons; 1993. p. 696
  19. Miyaura N, Suzuki A. *Chem. Rev* 1995;95:2457.
  20. Unpublished results
  21. Nugent WA. *J. Chem. Commun* 1999:1369.
  22. (a) Oppolzer W, Radinov RN. *Hev. Chim. Acta* 1992;75:170. (b) Pu L, Yu H-B. *Chem. Rev* 2001;101:757. [PubMed: 11712502]Review:
  23. Chen YK, Lurain AE, Walsh PJ. *J. Am. Chem. Soc* 2002;124:12225. [PubMed: 12371863]
  24. Honda T, Mizutani H, Kanai K. *J. Chem. Soc., Perkin Trans. 1* 1996;14:1729.




Scheme 1.



Scheme 2.




Scheme 3.




Scheme 4.





Scheme 5.



Scheme 6.